

Supplemental Table for:

Immune-related adverse events by immune-checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer

Hiroaki Akamatsu et al.

Supplementary Table S1. Analytes used in this study.

| | | | | | |
|----------------|-----------------|--------|----------|---------|------------|
| Angiopoietin-2 | BMP-9 | EGF | Endoglin | EOTAXIN | FGF-2 |
| Flt-3L | Follistatin | G-CSF | GM-CSF | GRO | HB-EGF |
| HGF | IFN- α 2 | IFN-g | IL-10 | IL-17 | IL-2 |
| IL-4 | IL-6 | IL-7 | IL-8 | IP-10 | Leptin |
| MCP-1 | MDC | MIP-1a | MIP-1b | PDGF-AA | PDGF-AB/BB |
| PLGF | RANTES | sCD40L | TGF-a | TGF-b1 | TGF-b2 |
| TGF-b3 | TNF-a | VEGF-A | VEGF-C | VEGF-D | |